Highlights from: The New Chemist’s Podcasting Group — The Path to KOLs: Accelerating First-in-Human in LATAM — Julio G. Martinez-Clark, CEO, bioaccess® w/ Chadwin Hanna, MD-PhD Student (UF) and David Ferguson (Host)
In this episode, on The Path to KOLs from The New Chemist’s Podcasting Group, hosts David Ferguson and Chadwin Hanna explore how Latin America is becoming a strategic engine for high-quality, cost-effective clinical research.
Julio G. Martinez-Clark—Ambassador of IAOCR/GCSA Americas and CEO of bioaccess®—breaks down how aligning to global competence standards and smarter site activation can compress timelines for First-in-Human and Early Feasibility Studies without compromising quality. He shares lessons from pioneering trials, practical blueprints for building city-level clinical hubs, and pragmatic guidance for innovators entering LATAM markets. The conversation also touches on sustaining regional infrastructure, cross-border collaboration, and the mindset behind his long-running Global Trial Accelerators™ series.
Guest: Julio G. Martinez-Clark, CEO, bioaccess®
Hosts: David Ferguson, BS, MS, Pharm.D. Candidate; Chadwin Hanna, MD Candidate & PhD Student
Please note: The views of this podcast reflect those of my guest(s) and I, and do not constitute medical advice, consultation and suggestions. Please see a board certified and state licensed medical professional.